Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer
882 BCG040, a novel B7-H4-targeting biparatopic ADC, demonstrates superior preclinical efficacy in heterogeneous tumors
- 1methodologist
- 2Biocytogen, Waltham, MA, USA
Related
- Robotic-assisted total knee arthroplasty demonstrates superior early functional outcomes compared with conventional total knee arthroplasty: a quasi-randomised controlled trial
- PN6047 demonstrates preclinical efficacy in headache models as a novel delta-opioid receptor agonist
- Spatially fractionated radiotherapy with PD-L1 blockade achieves superior antitumor efficacy and safety in a preclinical model of peritoneal metastasis
- 618 A novel preclinical mouse model to investigate IL-18-targeting therapies
- 401 genO-hCCR8/hCCL1/hFcγR preclinical mouse model for efficacy assessment of CCR8-targeting agents
BibTeX
@article{zhu2026bcg040,
title = {{882 BCG040, a novel B7-H4-targeting biparatopic ADC, demonstrates superior preclinical efficacy in heterogeneous tumors}},
author = {Ying Zhu and Yanan Guo and Peiran Li and Icy Niu},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
month = nov,
doi = {10.1136/jitc-2026-sitc2026.0882},
url = {https://doi.org/10.1136/jitc-2026-sitc2026.0882},
note = {CC BY},
}
RIS
TY - JOUR
TI - 882 BCG040, a novel B7-H4-targeting biparatopic ADC, demonstrates superior preclinical efficacy in heterogeneous tumors
AU - Ying Zhu
AU - Yanan Guo
AU - Peiran Li
AU - Icy Niu
PY - 2026
DA - 2026/11/06
JO - Journal for ImmunoTherapy of Cancer
DO - 10.1136/jitc-2026-sitc2026.0882
UR - https://doi.org/10.1136/jitc-2026-sitc2026.0882
SN - 2051-1426
ER -